36. Epidermolysis bullosa Clinical trials / Disease details


Clinical trials : 160 Drugs : 195 - (DrugBank : 47) / Drug target genes : 50 - Drug target pathways : 124

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04177498
(ClinicalTrials.gov)
August 24, 20217/11/2019Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCCA Pilot, Open Study to Assess Efficacy and Safety of Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated Locally Advanced/Metastatic Squamous Cell CarcinomaRecessive Dystrophic Epidermolysis BullosaDrug: Rigosertib Sodium;Other: Quality-of-Life AssessmentThomas Jefferson UniversityOnconova Therapeutics, Inc.Recruiting18 Years79 YearsAll6Early Phase 1United States